-
Johnson & Johnson to Participate in the Citi’s 2025 Global Healthcare Conference
Johnson & Johnson to Participate in the Citi’s 2025 Global Healthcare Conference
Share
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) will present at the Citi’s 2025 Global Healthcare Conference on Wednesday, December 3rd, 2025. Management will participate in a Fireside Chat at 11:15 a.m. Eastern Time.
A live audio webcast of the presentation will be accessible through Johnson & Johnson’s Investor Relations website at www.investor.jnj.com. An archived edition of the session will be available later that day.
The audio webcast replay will be available approximately 48 hours after the webcast.
Contacts
Media contact:
media-relations@its.jnj.com
Investor contact:
investor-relations@its.jnj.com
Johnson & Johnson
More News From Johnson & Johnson
Johnson & Johnson Reaches Agreement with U.S. Government to Improve Access to Medicines and Lower Costs for Millions of Americans; Delivers on U.S. Manufacturing and Innovation Investments
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) (the “Company”), healthcare’s leading, most comprehensive innovation powerhouse, today announced a voluntary agreement with the Trump Administration to improve access to medicines and lower costs for millions of American patients. The joint agreement meets the requests laid out by President Trump to the industry and provides the Company’s pharmaceutical products an exemption from tariffs1. “Today’s agreement shows that when...
Johnson & Johnson Submits OTTAVA™ Robotic Surgical System to the U.S. Food and Drug Administration
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson today announced that the company has submitted the OTTAVA™ Robotic Surgical System to the U.S. Food and Drug Administration (FDA) in an application for De Novo classification. Leveraging data from the Investigational Device Exemption (IDE) study, the company has applied for marketing authorization in multiple procedures in general surgery within the upper abdomen. “We have taken learnings from Johnson & Johnson’s 140 years in surge...
Johnson & Johnson Announces Quarterly Dividend for First Quarter 2026
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) today announced that its Board of Directors has declared a cash dividend for the first quarter of 2026 of $1.30 per share on the company’s common stock. The dividend is payable on March 10, 2026 to shareholders of record at the close of business on February 24, 2026. The ex-dividend date is February 24, 2026. About Johnson & Johnson At Johnson & Johnson, we believe health is everything. Our strength in healthcare in...
